Vesugen Peptides 20mg 10vials 1kits

Description

High purity Vesugen Research Peptide | Synthetic Vascular Tripeptide (Cytogen)

Mode of Action

The biochemical activity of Vesugen is dictated by direct epigenetic integration. Initially, the low-molecular-weight tripeptide permeates the nuclear envelope via simple passive diffusion without requiring energy-dependent macromolecular transporter complexes. This defines the first semantic triple: [Vesugen penetrates the endothelial nuclear core]. It opens chromatin lines. Following this, the negatively charged residues within the KED configuration dock securely into the major grooves of double-stranded DNA to alter local nucleoprotein charges. This establishes the second triple: [Vesugen binding decondenses transcriptionally silent heterochromatin]. This structural shift frees silenced loci. Furthermore, this targeted spatial unwinding exposes hidden promoter regions, initiating immediate gene activation. This forms the third triple: [Chromatin remodeling upregulates vascular endothelial growth factor transcription]. Quantitatively, Vesugen exhibits a brief systemic plasma half-life of approximately 20 minutes ($t_{1/2} = 20.0 pm 3.5$ min) driven by localized plasma aminopeptidase cleavage velocities, but the downstream transcriptional modifications maintain a prolonged cellular footprint for up to 48 hours. In comparative studies, Vesugen is strictly distinguished from the copper-binding analog GHK-Cu; while GHK-Cu functions as a broad-spectrum copper chaperone driving systemic extracellular matrix remodeling and tissue macro-healing across multiple tissue types, Vesugen operates strictly via direct, receptor-independent nuclear signaling to induce tissue-specific microvascular endothelial proliferation.

Product Profile

Vesugen is a synthetic tripeptide. [Vesugen upregulates endothelial cell differentiation factors]. This highly pure biopolymer compound focuses its target-specific biological activity on the structural stabilization and transcriptional maintenance of vascular endothelial cell linings under oxidative or age-related tissue stress. It penetrates cells easily. This unhindered cellular entry facilitates high-affinity coordinate binding directly with nuclear matrix lines, turning on localized protein synthesis profiles without triggering peripheral endocrine or off-target receptor feedback paths.

Molecular Data

• Amino Acid Sequence: L-Lysyl-L-Glutamyl-L-Aspartic Acid (Lys-Glu-Asp / KED)
• CAS Number: 204271-66-9
• Molecular Formula: C15H26N4O8
• Molecular Weight: 390.39 g/mol
• Purity: >99.0% via HPLC-UV verification
• Appearance: Fine white to off-white lyophilized powder cake

Known Effects

• Microvascular Perfusion Enhancement: Users in research models report a pronounced optimization of localized capillary blood flow parameters under intense ischemic stress.
• Endothelial Barrier Optimization: Experimental findings suggest enhanced cellular tightness and a noticeable stabilization of vascular wall permeability profiles.
• Atherosclerotic Plaque Resistance: According to research documentation, research assays demonstrate a marked down-regulation of vascular cell adhesion molecules inside challenged vascular beds.
• Upregulated Nitric Oxide Synthesis: Multiple research groups note optimized endothelial nitric oxide synthase translation, reinforcing normal vessel diameter regulation.
• Attenuated Cellular Senescence: Research models have observed a distinct shift of aged vascular tissues back toward a youthful, transcriptionally active operational state.

Key Points:
Vesugen represents a premier, target-specific short peptide research tool for investigating direct epigenetic chromatin remodeling and the molecular pathways of vascular tissue preservation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.